BMJ  2007;335:1248-1251 (15 December), doi:10.1136/bmj.39398.682500.25 (published 23 November 2007)

Research

Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis

¹ Department of Anaesthesiology, Rigshospitalet, Juliane Marie Centre, University of Copenhagen, Copenhagen, Denmark, ² Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, ³ Cochrane Anaesthesia Group, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Ø, Copenhagen, Denmark

Objective To evaluate the benefits and harms of antithrombin III in critically ill patients.

Design Systematic review and meta-analysis of randomised trials.

Data sources CENTRAL, Medline, Embase, International Web of Science, LILACS, the Chinese Biomedical Literature Database, and CINHAL (to November 2006); hand search of reference lists, contact with authors and experts, and search of registers of ongoing trials.

Review methods Two reviewers independently selected parallel group randomised clinical trials comparing antithrombin with placebo or no intervention and extracted data related to study methods, interventions, outcomes, bias risk, and adverse events. Disagreements were resolved by discussion. Trials in any type of critically ill patients in intensive care were eligible. All trials, irrespective of blinding or language status, that compared any antithrombin III regimen with no intervention or placebo were included. Trials were considered to be at low risk of bias if they had adequate randomisation procedure, blinding, and used intention to treat analysis. Risk ratios with 95% confidence intervals were estimated with fixed and random effects models according to heterogeneity.

Main outcome measures Mortality, length of stay in intensive care or hospital, quality of life, severity of sepsis, respiratory failure, duration of mechanical ventilation, incidence of surgical intervention, intervention effect among various populations, and adverse events (such as bleeding).

Results 20 trials randomly assigning 3458 patients met inclusion criteria. Eight trials had low risk of bias. Compared with placebo or no intervention, antithrombin III did not reduce overall mortality (relative risk 0.96, 95% confidence interval 0.89 to 1.03). No subgroup analyses on risk of bias, populations of patients, or with and without adjuvant heparin yielded significant results. Antithrombin III increased the risk of bleeding events (1.52, 1.30 to 1.78). Heterogeneity was observed in only a few analyses.

Conclusion Antithrombin III cannot be recommended for critically ill patients based on the available evidence.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Reasons for optimism

Rajendra Kale
BMJ 2007 335: 0. [Extract] [Full Text]

Antithrombin III in critically ill patients

A Torossian, J Graf, and A Bauhofer
BMJ 2007 335: 1219-1220. [Extract] [Full Text] [PDF]

Statistics Notes: Interaction revisited: the difference between two estimates

Douglas G Altman and J Martin Bland
BMJ 2003 326: 219. [Extract] [Full Text] [PDF]

Why we need a broad perspective on meta-analysis

Peter C Gøtzsche
BMJ 2000 321: 585-586. [Extract] [Full Text] [PDF]

Bias in meta-analysis detected by a simple, graphical test

Matthias Egger, George Davey Smith, Martin Schneider, and Christoph Minder
BMJ 1997 315: 629-634. [Abstract] [Full Text]

This article has been cited by other articles:

• (2008). Antithrombin III Has No Benefit in Critically Ill Patients. JWatch Emergency Med. 2008: 3-3 [Full text]  
• (2007). Critically Ill Patients Do Not Benefit from Antithrombin III. JWatch General 2007: 2-2 [Full text]  
• Torossian, A, Graf, J, Bauhofer, A (2007). Antithrombin III in critically ill patients. BMJ 335: 1219-1220 [Full text]  

Rapid Responses:

Read all Rapid Responses

Heparin to stop bleeding after cardiopulmonary bypass

Friedrich Flachsbart
bmj.com, 16 Dec 2007 [Full text]